Advertise on podcast: The Simple BioTech Podcast

Today is a very special episode where I will be discussing Biotech and Blockchain. Now you might be asking yourself - how do blockchain and biotech have anything to do with each other? That's exactly what i thought as well when I first heard of VitaDao. But after my conversation today I'm convinced that this is a collision of industries that was absolutely necessary. Vitadao is taking the world of crypto, and the world of BioTech and smashing them together in an explosion of innovation.  VitaDao is a completely decentralized autonomous organization... also know as a DAO... now there's a high likelihood that that sounds like a foreign language, and that a lot of you have never heard of a decentralized autonomous organization.. fear not, we go deep into exactly what that means in this episode. VitaDao is allowing any investor to invest in the absolute cutting edge BioTech technologies... the type of technologies that have so much potential, but carry so much risk, that the typical institutional investor or VC will pass on. This conversation blew me away... just wait until you hear what they're doing with BioTech IP and NFTs. I don't want to spoil too much but this is an episode you won't want to miss. Podcast notes and transcript available here: https://simplebiotechpodcast.com/tyler-golato-vitadao -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Locked in every bite of food we take is a universe of hidden potential. Potential to cure disease, help our sleep, and improve our mood just to name a few. The food we eat has a galaxy of molecules we call peptides, these peptides have limitless possibilities that get destroyed by the black hole we call our digestive system. These peptides have some truly miraculous healing qualities, but because of the extreme weakness in their bioavailability, to date humans have not been able to experience the benefits.  Enter Nuritas - a company focusing on finding these miraculous peptides using AI technology, and extracting them from the food to become more bioavailable, essentially unlocking the full potential of the food that we eat. Dr. Nora khaldi is the brilliant woman behind Nuritas and today i had the pleasure of diving deep into the weeds with her while she explained just how this technology works, and what it means for human civilization going forward. So without further ado, Dr. Nora Khaldi. Podcast notes and transcript available here: https://simplebiotechpodcast.com/nora-khaldi-nuritas -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

What if I were to tell you that each and every one of us has a universe inside of us that controls our mood, how we age, and even what we're allergic to. A universe inside of our guts filled with trillions of microorganisms that make up our gut microbiome that dictate our lives from the moment we're born. Having a healthy gut microbiome from birth is a massive part of living a long, happy life. However, in recent years, because of changes to how we raise our children researchers have noticed that infants of today have less and less of these extremely important bacteria which can cause life long issues for babies that are born today. This is a serious issue, on a global scale, and it's one that can't be ignored. My guest today is an absolute stud in the world of biotech, and is tackling this issue head on with Evolve Biosystems. In this interview I get educated on the different strains of probiotics, why they're so important, why the children born today have less of them and why that is such a problem, as well as some tips for adults that have nuked their guts with things like antibiotics. My guest today... Chief Science Officer and Chairman of Evolve Biosystems, David Kyle. Podcast notes and transcript available here: https://simplebiotechpodcast.com/david-kyle-evolve-biosystems -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Imagine if you could turn the characteristics of a cell on and off… or up and down like a volume trigger… constantly tuning things until everything is working just right. It might sound impossible, but that’s exactly what Obsidian therapeutics is working on. I’ll admit, it was tough for me to wrap my mind around this one at first, but my guest today did a fantastic job of explaining things. So without further ado, chief development officer of Obsidian therapeutics, Catherine Stehman-Breen. Podcast notes and transcript available here: https://simplebiotechpodcast.com/catherine-stehman-breen-obsidian-therapeutics -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Everyone's dealt with anxiety and depression to some extent, at some point in their lives. It can be debilitating and can cause feelings of hopelessness and helplessness. My guest, Shawn Singh wants to change that. Him and his company, Vistagen Therapeutics are taking on anxiety and depression with their unique bio technology that aims to leave the nasty side effects of anxiety and depression meds behind Vistagen Therapeutics is a publicly traded company on the Nasdaq stock exchange under the ticket VTGN. If you are someone who's dealt with either anxiety or depression this episode is for you. Podcast notes and transcript available here: https://simplebiotechpodcast.com/shawn-singh-vistagen-therapeutics -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Imagine being blind and you can see again. Imagine being paralyzed and you can move again. Imagine how amazing it would feel to be cured of cancer. Life changing would be an understatement. My guest today is the CEO of a company that is leading the way in cell therapy, a technology that can do just that; cure the blind, give movement to the paralyzed, and cure cancer. Brian Culley is the CEO of Lineage Cell Therapeutics, a publicly traded company on the NYSE. Stock ticker: LCTX Lineage Cell Therapeutics has had some extremely promising results by using the power of Pluripotent stem cells. This was a fascinating and exciting conversation and Brian does a great job of explaining complicated subjects so the average person can understand. If you're curious about the almost magic like power of Pluripotent stem cells, and all that they can do, than this is a must listen. Podcast notes and transcript available here: https://simplebiotechpodcast.com/brian-culley-lineage-cell-therapeutics -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

If you've lived in the twentieth century you've likely, at one point or another, had an attachment to a non human furry friend... and with any attachment comes the inevitable realization that our furry friend is a mere mortal... one that will age, slow down, and become frail in our life time. If this is something you dread, then this episode is for you. In this day and age we live so closely with our pets that they've become members of the standard twentieth century family... and losing a pet is just like losing a family member. My guest today is a man that is attempting to drastically slow down the aging process of our furry best friends, and to extend the amount of healthy, happy, time that we have with them. Nick Sinclair is the CEO of Animal Bioscience, one of the 5 daughter companies of famed David Sinclair's Life Biosciences. In this fascinating interview Nick helps explain to me just how they are tackling animal aging, how it's different than tackling human aging, how the discoveries in animal aging will actually help progress the science in human aging, and a plethora of other interesting topics. If you're interested in getting an inside look into the world of Longevity, you'll love this episode. Podcast notes available here: https://simplebiotechpodcast.com/ -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

If you're confused about NAD and it's precursors then this is the podcast for you. Dr. Joseph Baur, an Associate Professor of Physiology from University of Pennsylvania, is a leading NAD researcher. His lab currently studies metabolic and signaling pathways by which nutrient intake can influence longevity, with a particular emphasis on NAD and mTOR. In this interview Joseph breaks down all the questions I've had (and there's a lot) about the miracle molecule, NAD. Joseph helps me to understand why it's such an important molecule, how one can boost NAD levels, and what the data tells us about the different NAD precursors, NMN & NR. As you may or not know there is quite a bit of debate about which NAD precursors work best, and if they even work at all to boost NAD levels in a way that will extend lifespan in humans. It was an absolute pleasure to have a non biased guest on the podcast to help clear things up and explain the cold, hard science. If you've seen the hundreds of podcasts out there talking about NAD, NMN, and NR and you're still confused - this episode should help. Podcast notes available here: https://simplebiotechpodcast.com/joseph-baur-nad-nmn-nr/ -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Dr. Gregory Bailey is the CEO of Juvenescence, one of the biggest players in the Longevity industry. Dr. Bailey has a medical degree from the University of Western Ontario and practiced emergency medicine for more than 10 years before entering the world of finance. We talked about all the different things that Juvenescence is working on, as well as some great tips for investing in the capital starved longevity industry. If you want some advice from one of the top investors in the industry, make sure to give this a listen. Juvenescence has their hands in a lot of different pies... from participating in strategic investments where they know they can add significant value as a company, to launching products like Metabolic Switch, which can instantly turn you into ketosis, due to premier this year. The longevity industry is starved for cash, but it can be extremely daunting for someone with no formal medical training to make an intelligent investment. Dr. Bailey gives some great advice for getting around this hurdle. It was an absolute honor to speak with Dr. Gregory Bailey, and the conversation got me more excited than ever to play whatever small part I can in the industry. As his partner Jim Mellon says, this is the greatest investment opportunity in all of human history. Don't sleep on it. -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Alex Zhavoronkov is a particularly high level human being, originally working in the field of computer science, Alex had a realization that contributing to aging and aging research would be the biggest contribution he could make for humanity. Utilizing his expertise in computer science and artificial intelligence, he began using these skills to enter the world of longevity in a significant way. Artificial intelligence will play a massive role in drug and biomarker discovery going forward and Alex's company, Insilico Medicine is leading the charge in a serious way. It was an absolute honor to speak with Alex Zhavoronkov as he explained in simple terms just how exciting Insilico's tech is. How it works, all the different projects they are involved in, and just how much of a financial behemoth Insilico has the potential to be. (Keep an eye out for their IPO in the next few years) -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Andy Koff is the Founder of Atropos Therapeutics. A company with a new approach to tackling senescent cells, one fo the biggest hallmarks of aging. Atropos Therapeutics uses a bio marker to identify when a cell starts transitioning from a quiescent cell into a senescent cell. Using this bio marker, Atropos aims to be able to prevent the cell from transitioning into a senescent cell, they've dubbed this type of technology a "senosuppressant" For 25 years or so, starting with his post-graduate work at the Fred Hutchinson Cancer Center with Jim Roberts, and into his faculty position at Memorial Sloan Kettering Cancer Center, Andy has used a multitude of approaches, biochemical, genetic and cellular, to identify the proteins and the mechanisms that control how cells choose between duplicating themselves, known as proliferating, or remaining in a non-proliferating state.  This decision is incorrectly made in virtually all cancer cells, thus providing the framework to explain much about how drugs work in oncology. About five years ago, Andy’s attention shifted to another decision…how cells maintain themselves in the non-proliferating state and what might be the consequences to not being able to do so. His work today has applications in both oncology and in aging and age-related diseases. -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle

Mike West is a legend in the field of Gerontology, the study of aging. Back in the 90's, Mike's company Geron Corp, was the first company to not only successfully isolate embryonic stem cells, but to also isolate the telomerase gene, also known as the immortalizing gene. Gerons discoveries were so significant they prompted the former President of the United States to address the nation. It was an absolute honor to speak with Mike West, who is currently the CEO of Age X Therapeutics. The conversation, initially planned for only 30 minutes, flew by as it turned into an hour and a half long, mind blowing conversation about pluripotent stem cells, telomerase, and the absolute sci fi levels of potential behind these technologies. Arnold Schwarzenegger babies, glowing dogs, a 600 year human life span, and growing replacement organs in a petri dish are just a few of the topics we discussed on today's episode. Strap in, because this conversation is going to take you into orbit. -James Ruhle, SimpleBioTechPodcast.com Stay up to date with the latest episodes and BioTech updates by following me on instagram @SimpleBioTech If you want to know which BioTech companies I'm currently excited about, connect with me on Angel List at Angel.co/jamesruhle